
    
      In the stage IIIB/IIIC/IV NSCLC, patients received Toripalimab Injection (PD-1 inhibitor)
      240mg, d1; CTL cells venous re-transfusion >=1x10^9, d14; Q3W; till disease progresion, or
      intolerable adverse reactions.
    
  